Abstract
A dedicated stereotactic gamma irradiation device, GammaPod™ from Xcision Medical Systems, has been developed to treat early stage breast cancer. GammaPod™ offers the opportunity to deliver curative doses of radiation using stereotactic body radiotherapy (SBRT) more precisely than current radiotherapy standards, thereby minimizing the amount of breast tissue ablated and improving cosmesis. In this chapter, we review the current status of radiotherapy for breast cancer patients diagnosed with early stage disease and rationale for the development of a dedicated breast stereotactic system. Furthermore, a detailed description of the GammaPod technology, design specifications and its dosimetric characteristics are presented using comparative treatment planning studies in addition to dosimetric measurements from pre clinical prototype testing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
Christian MC, McCabe MS, Korn EL, Abrams JS, Kaplan RS, Friedman MA. The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Engl J Med. 1995;333:1469–74.
Knobf MT, Sun Y. A longitudinal study of symptoms and self-care activities in women treated with primary radiotherapy for breast cancer. Cancer Nurs. 2005;28:210–8.
Turnbull LW, Brown SR, Olivier C, Harvey I, Brown J, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess. 2010;14:1–182.
Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, Morrow M. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg. 2009;209:180–7; quiz 294–5.
Kuhl C, Kuhn W, Braun M, Schild H. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast. 2007;16 Suppl 2:S34–44.
Morrow M. Should routine breast cancer staging include MRI? Nat Clin Pract Oncol. 2009;6:72–3.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.
Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102.
Vaidya JS, Baum M, Tobias JS, Morgan S, D’Souza D. The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer. Eur J Surg Oncol. 2002;28:447–54.
NSABP B-39, RTOG 0413: A Randomized Phase III Study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin Adv Hematol Oncol. 2006;4:719–21.
Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, et al. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95–17. Int J Radiat Oncol Biol Phys. 2008;72:467–73.
Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–7.
Polgár C, Fodor J, Major T, Németh G, Lövey K, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma—5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.
Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. Breast J. 2010;16:245–51.
Scanderbeg D, Yashar C, White G, Rice R, Pawlicki T. Evaluation of three APBI techniques under NSABP B-39 guidelines. J Appl Clin Med Phys. 2009;11:3021.
Gupta S, Scanderbeg DJ, Kamrava M, Yashar CM. Unexpected toxicity in a patient treated with 3D conformal accelerated partial breast radiotherapy. Brachytherapy. 2009;8:207–9.
Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010; 76:71–8.
Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1290–6.
Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 1995;31:753–64.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.
Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol. 2006;45:779–86.
Nataf F, Schlienger M, Liu Z, Foulquier JN, Grès B, et al. Radiosurgery with or without a 2-mm margin for 93 single brain metastases. Int J Radiat Oncol Biol Phys. 2008;70:766–72.
Timmerman R, Abdulrahman R, Kavanagh BD, Meyer JL. Lung cancer: a model for implementing stereotactic body radiation therapy into practice. Front Radiat Ther Oncol. 2007;40:368–85.
Hadziahmetovic M, Loo BW, Timmerman RD, Mayr NA, Wang JZ, et al. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer—updates of radiobiology, techniques, and clinical outcomes. Discov Med. 2010;9:411–7.
Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.
Timmerman RD. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: who’s down for the count? J Clin Oncol. 2010;28:907–9.
Bondiau PY, Lallement M, Bahadoran P, Birtwisle-Peyrottes I, Chapellier C, et al. CyberKnife and neoadjuvant chemotherapy for breast tumors: preliminary results. Cancer Radiother. 2009;13: 79–84.
Bondiau PY, Bahadoran P, Lallement M, Birtwisle-Peyrottes I, Chapellier C, et al. Robotic stereotactic radioablation concomitant with neo-adjuvant chemotherapy for breast tumors. Int J Radiat Oncol Biol Phys. 2009;75:1041–7.
Yu XC. US National Cancer Institute 4R44CA132254-02; 2010.
Nichols EM, Dhople AA, Mohiuddin MM, Flannery TW, Yu CX, Regine WF. Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early-stage breast cancer: implications for the future. Int J Radiat Oncol Biol Phys. 2010;77:197–202.
Li X, Zhang J, Wang C, Yu C. Stereotactic radiation therapy for breast cancer: dosimetry feasibility. Int J Radiat Oncol Biol Phys. 2010;78:S139.
Mutaf YD, Yu C, Zhang J, Prado K, Feigenberg S, et al. Dosimetric characterization of a novel stereotactic radiotherapy device for breast cancer. Radiother Oncol. 2011;99(S1):S160–1.
Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1–2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–90.
Faverly DR, Hendriks JH, Holland R. Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer. 2001;91:647–59.
Nichols EM, Feigenberg SJ, Marter K, Lasio G, Cheston SB, et al. Pre-operative therapy increases patient eligibility for accelerated partial breast irradiation (APBI) and decreases normal tissue exposure. Int J Radiat Oncol Biol Phys. 2010;78:S251.
Yu C, Feigenberg S. Radiat Oncol (London, England). Rad. Onc.journal. 2011; 99:S305.
Nelson WR, Hirayama H, Rogers DW. Electron-photon transport using the EGS4 Monte Carlo code. Trans Am Nucl Soc. 1986;52:379–80.
Kawrakow I, Walters BR. Efficient photon beam dose calculations using DOSXYZnrc with BEAMnrc. Med Phys. 2006;33:3046–56.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mutaf, Y.D., Yu, C., Feigenberg, S.J., Regine, W.F. (2015). GammaPod. In: Chin, L., Regine, W. (eds) Principles and Practice of Stereotactic Radiosurgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8363-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8363-2_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8362-5
Online ISBN: 978-1-4614-8363-2
eBook Packages: MedicineMedicine (R0)